1. Scrip
  2. >>New Products

Bayer Focusing On Early CKD Testing In Kerendia US Launch

Less Than 50% Of Doctors Use UACR For Earlier Diagnosis

 
• By Mandy Jackson

The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.

Human kidneys medicine treatment concept
Kerendia (finerenone) is a kidney disease-specific treatment for CKD associated with diabetes • Source: Alamy

Bayer AG brought in a new sales team specifically to promote Kerendia (finerenone) in the US for chronic kidney disease (CKD) in patients with type 2 diabetes, and those representatives will hit the ground running later this month. The US Food and Drug Administration approved the non-steroidal mineralocorticoid receptor antagonist on 9 July and the company is working to manufacture enough of the once-daily pills to distribute the product to retail pharmacies within the next two weeks.

Kerendia is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.